Meredith Schultz, M.D., M.S.

Chief Medical Officer

Meredith Schultz, M.D., M.S., is a pediatric neurologist experienced in treating patients with rare and neurogenetic disorders, including Rett syndrome. Dr. Schultz brings more than 17 years of clinical experience, including treating patients as a Principal Investigator on several pivotal trials for Zolgensma for the treatment of spinal muscular atrophy, and she has led numerous gene therapy clinical trials for rare diseases throughout her career, including programs in Huntington’s Disease, Friedreich’s Ataxia, leukodystrophies, neuro-metabolic disorders, and neurodegenerative disorders. Before joining Taysha, Dr. Schultz served as Vice President at Asklepios BioPharmaceutical, Inc. Prior to that, Dr. Schultz served in leadership positions at AveXis Inc. and Novartis Gene Therapies.